BOSTON: T3D Therapeutics was chosen as a late-breaking addition to the Alzheimer’s Association International Conference (AAIC) this year in Toronto. On Wednesday, July 27, 2016, T3D Therapeutics will present “Rapid Onset of Cognitive Improvements in a Subset of Mild and Moderate Alzheimer’s Patients Treated with T3D-959: Interim Results of a Phase 2a Open Label Clinical Trial” at the conference.